OncoMatch/Clinical Trials/NCT06433947
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Is NCT06433947 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including OPN-6602 and Dexamethasone for relapsed multiple myeloma.
Treatment: OPN-6602 · Dexamethasone — Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory agent
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
Must have received: proteasome inhibitor
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
Must have received: anti-CD38 antibody
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
Cannot have received: autologous peripheral stem cell transplant
Exception: allowed if >90 days before first dose
Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within <90 days of the first dose of study drug
Cannot have received: autologous bone marrow transplantation
Exception: allowed if >90 days before first dose
Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within <90 days of the first dose of study drug
Cannot have received: allogeneic stem cell transplantation
Exception: allowed if >12 months before screening and not receiving immunosuppressive medication for active graft vs host disease
Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of screening; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.
Cannot have received: solid organ transplantation
Exception: allowed if >12 months before screening and not receiving immunosuppressive medication for active graft vs host disease
Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of screening; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.
Cannot have received: chemotherapy
Exception: allowed if >2 weeks before first dose
Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug
Cannot have received: targeted anticancer therapy
Exception: allowed if >2 weeks before first dose
Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug
Cannot have received: radiation therapy
Exception: allowed if >2 weeks before first dose
Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug
Cannot have received: localized radiation therapy
Exception: allowed if >2 weeks before first dose
Localized radiation therapy to disease site(s) within 2 weeks of the first dose
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Adequate hematologic, renal, liver, cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson · Gilbert, Arizona
- Stanford Cancer Institute · Stanford, California
- Emory Winchip Cancer Center · Atlanta, Georgia
- University of Kansas Clinical Research Center · Westwood, Kansas
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06433947 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous peripheral stem cell transplant, autologous bone marrow transplantation, allogeneic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages